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Periodontitis is a chronic inflammatory condition of the tissues that surround and support the teeth and is initiated by inappropriate
and excessive immune responses to bacteria in subgingival dental plaque leading to loss of the integrity of the periodontium,
compromised tooth function, and eventually tooth loss. Periodontitis is an economically important disease as it is time-consuming
and expensive to treat. Periodontitis has a worldwide prevalence of 5–15% and the prevalence of severe disease in western
populations has increased in recent decades. Furthermore, periodontitis is more common in smokers, in obesity, in people with
diabetes, and in heart disease patients although the pathogenic processes underpinning these links are, as yet, poorly understood.
Diagnosis and monitoring of periodontitis rely on traditional clinical examinations which are inadequate to predict patient
susceptibility, disease activity, and response to treatment. Studies of the immunopathogenesis of periodontitis and analysis of
mediators in saliva have allowed the identification of many potentially useful biomarkers. Convenient measurement of these
biomarkers using chairside analytical devices could form the basis for diagnostic tests which will aid the clinician and the patient
in periodontitis management; this review will summarise this field and will identify the experimental, technical, and clinical issues
that remain to be addressed before such tests can be implemented.
1. Introduction
1.1. The Clinical Importance of Periodontitis. Periodontitis
and gingivitis are the most common forms of periodontal
disease; these disorders are caused by disruption to normal
homeostatic processes by numerous bacterial species found
in subgingival dental plaque [1] and are modified by envi-
ronmental and genetic factors [1, 2]. Gingivitis is a superficial
inflammation of the gingiva (gums) and, although gingivitis
is very prevalent, this disorder is effectively reversible with
oral hygiene regimens. Periodontitis is a substantial destruc-
tive inflammatory condition of the anatomical structures
which surround and support the teeth, namely, the gingiva,
the periodontal ligament, and the alveolar bone [2]. This
results in tissue injury including loss of connective tissue
attachments and alveolar bone destruction. Consequently,
periodontitis often results in loose teeth, pain, and impaired
mastication and is a common cause of tooth loss [2]. Further-
more, periodontitis is time-consuming and expensive to treat
and, therefore, prevention, early detection, and management
of extent of the disease are critical issues [3]. Also, periodonti-
tis patients have significantly poorer physical, psychological,
and social oral-health-related quality of life measures as
compared to periodontal healthy individuals [4].
There is a global variation in the prevalence, severity,
and progression of periodontitis [2, 5]. The prevalence of
periodontitis is 5–15% of adults globally [5] with some
geographic variation; for example, in Asia the prevalence is
as high as 15–20% [6]. Some 9% of the UK population suffer
from advanced periodontitis according to the 2009 Adult
DentalHealth Survey (ADHS) as compared to 6%as recorded
by the 1998 ADHS suggesting that there is an increasing
trend toward more severe disease in the UK, possibly due to
greater retention of natural teeth [7]. Also, some 15% of the
UK population over 55 years of age have severe periodontal
disease.
Clinical and epidemiological evidence reveals an associa-
tion between chronic periodontitis and a number of systemic
conditions, most notably diabetes and cardiovascular disease
(CVD) [8, 9]; these associations are likely to be mediated by
common pathogenic pathways [10, 11]. There is also evidence
from a number of cross-sectional studies for an association
between periodontitis and obesity [12] and some suggestion
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of an inverse relationship between sustained physical activity
and periodontitis [13], although there is a recognised need for
prospective cohort studies to firmly establish the clinical and
pathogenic associations between these conditions [8]. Thus,
an ageing population making poor diet and lifestyle choices
is increasing the healthcare burden of periodontitis world-
wide. Furthermore, many other diseases have periodontal
manifestations including systemic infectious disease (e.g.,
HIV/AIDS) and some rare genetic disorders (e.g., Papillion-
Lefe`vre Syndrome) [2]. Significantly, the results of several
meta-analyses of clinical studies show that treatment for
periodontitis is associated with an improvement in glycaemic
control in diabetic patients suggesting that management
of periodontitis may have beneficial effects beyond oral
healthcare [8]. It is established that smoking is a major
risk for incidence and progression of periodontitis [14] and
smoking cessation has a favourable impact on periodontitis
[15]. The complex relationships of periodontitis with other
diseases and risk factors suggest that the elements involved
in maintenance of periodontal homeostasis, breakdown, and
repair are similarly complex (see below).
1.2. The Role of Biomarkers in the Clinical Management of
Periodontitis. Currently, there are no dependable tests to
diagnose and predict progression of periodontitis. Although
clinical diagnosis of periodontitis based on visual and radio-
graphic assessment in addition to measurement of pocket
depth, tissue attachment, and “bleeding on probing” (BOP)
in different locations in multiple teeth is well established in
dental practice, these are time-consuming procedures for the
periodontist [2]. There is a requirement for tests that tell
the clinician more than the conventional diagnostic tools at
his/her disposal, for example, visual changes, clinical assess-
ment (e.g., BOP), and radiographs; these traditional diagnos-
tic procedures give an indication of severity and, therefore,
reflect historical disease activity but not current disease
activity and they do not identify susceptible individuals who
might be at risk of future periodontitis [16]. The application
of scientific evidence and patient-specific information is now
considered to be central to effective clinical management
of periodontitis [17]. Lack of evidence-based knowledge of
individual patients’ disease may lead to clinical mismanage-
ment, for example, failure to identify disease activity and
inappropriate antimicrobial therapy [3]. The requirement for
reliable biomarkers to distinguish progressive periodontitis
from normal biological processes is considered fundamental
to identify periodontitis at an earlier or even preclinical stage,
to initiate preventative pretreatment, and also to conduct
epidemiological studies [3, 18].
The concept of a biomarker arose from the recogni-
tion of the appeal of being able to monitor health status,
disease susceptibility, progression, resolution, and treatment
outcome with respect to a number of common medical
conditions [19]. Biomarkers have been defined as “cellular,
biochemical, molecular, or genetic alterations by which a
normal, abnormal, or simply biologic process can be recog-
nized or monitored” [20]. Biomarkers must be indicative of
physiological health, pathological processes, and/or response
to therapy. Also, biomarkers must be discriminatory, robust,
and validated in clinical studies. However, although a number
of potential biomarkers are under investigation for diagnosis
of oral and systemic diseases, a suitable marker for the
detailed investigation of periodontal disease remains to be
fully characterised.
1.3. Salivary Proteins as Biomarkers of Periodontitis. The holy
grail of biomarker research in periodontology is to develop
a “high impact diagnostics” which have a significant impact
on clinical decisionmaking, patient outcomes, andhealthcare
economics [21] equivalent to existing clinical tests, such as
prostate specific antigen testing, HIV viral load analysis,
HbA1c, and cholesterolmonitoring.Many studies of potential
biomarkers in the periodontitis literature have historically
focussed on analysis of gingival crevicular fluid (GCF) which
is a serum transudate originating from the gingival blood
vessels which lie close to the epithelial surface of the den-
togingival junction, as reviewed elsewhere [22–24]. Although
a number of promisingmarkers have been identified, analysis
of GCF reflects disease activity at individual tooth sites
rather than the whole mouth, a fact which complicates
interpretation. There are also technical issues concerning
the use of GCF: collection of GCF is a time-consuming,
skilled and cumbersome procedure. Also, measurement of
collected GCF volume and analyte concentrations is fraught
with difficulty due to the very small volumes obtained.
Nonetheless, a number of promising biomarkers identified
in GCF have also been revealed to be potential salivary
biomarkers for periodontitis [24].
Saliva comprises the components of exocrine secretions
of the oral salivary glands as well as GCF and elements
of dental plaque and the diet; the anatomy and physiology
of saliva secretion and the detailed composition of saliva
are reviewed elsewhere [20, 25]. It has been recognised for
some years that saliva shows particular promise in terms
of identifying useful biomarkers and developing convenient
technologies to measure these in the clinic and (potentially)
at home [19, 26]. Saliva is advantageous as it is abundant
and readily accessible through noninvasive and painless
procedures which will make clinical trial involvement more
attractive for the patient. Also, it is cheap to collect and does
not require trained medical or dental staff, and collection is
not hampered by issues relating to clotting. It is possible to
detect markers in saliva at low levels although some high
abundant proteins in saliva, for example, amylase, albumin,
and immunoglobulins, may interfere with the detection of
less abundant proteins [27]. Salivary analysis has been pro-
posed for widespread assessment of systemic disease includ-
ing cancer, viral infections, and screening and investigation of
oral disease [19, 28].This includes an FDA approved at-home
test for HIV based on analysis of saliva. Other applications of
salivary analysis include drug detection and genetic analysis,
for example, for pharmacogenetic applications.
Salivary diagnostic tests for periodontal disease include
those based on analysis of molecular components, peri-
odontal pathogens, and DNA for putative genetic risk [28,
29]. In terms of periodontal diagnosis, whole saliva not
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only is advantageous for its ease of collection but also has
elements which reflect the activity of all periodontal sites
and therefore provides an indication of disease status in
the mouth as a whole rather than at individual sites as
with GCF analysis. However, salivary analysis of periodontal
pathogens has not proven successful as a diagnostic marker
for periodontitis [30, 31]. This perhaps reflects the fact that
clinical presentation of disease is not necessarily explained
by the content and anatomical distribution of dental plaque
and its constituent bacteria [3]. Also, our knowledge of the
genetic basis for periodontitis is in its infancy so, whereas
analysis of salivary DNA is possible, there are no univer-
sally accepted genetic tests applicable to periodontal disease
diagnosis. For information relating to the use of genetic
markers and microbiological analysis in periodontal disease
diagnosis the reader is referred to excellent recent reviews
[31, 32]. Other mediators which have also been investigated
as candidate biomarkers for periodontitis including Ca2+,
cortisol, hydrogen sulphide, and 8-hydroxy-deoxyguanosine
have also been the subject of recent review [31]. The present
review will be limited to a discussion of salivary proteins as
biomarkers of periodontitis and their clinical utility.
2. Aetiology and Pathogenesis of Periodontitis
2.1. Inflammatory Processes in Periodontitis. Although the
microbial components of the subgingival plaque biofilm are
the aetiological factors, the pathogenesis of periodontitis is a
complex interaction between the microbiota and host tissues
modified by environmental factors in particular smoking,
age, systemic disease, and genetic susceptibility. Our knowl-
edge of the complexity, dynamics, and properties of the
dental plaque biofilm is substantial [33]; nonetheless, a major
paradigm shift in the understanding of periodontitis was the
appreciation that the nature and extent of the host response
to the dental plaque biofilm are a fundamental determinant
in susceptibility and progression in periodontal disease [34–
36]. Indeed, the relationships between different presentations
of periodontal disease (e.g., gingivitis, periodontitis), disease
progression, and histological features are well-established
[36, 37] and, in terms of immunopathogenesis, substantial
(albeit mostly indirect) evidence exists to relate immune cell
diversity and distribution to the action of certain molecu-
lar mediators and, in particular, cytokines [36, 38]. More
recently, we have developed an intricate knowledge of the
processes that drive innate responses to plaque bacteria [1],
the activation of adaptive immune responses (and especially
T-cell subsets) [39], and the integration of immune regulation
and connective tissue (including bone) homeostasis [40].
The molecular basis of resolution of chronic inflammation
is also under scrutiny and has revealed new possibilities for
therapeutic intervention [41].
There are many molecular signals which regulate inflam-
matory processes such as periodontitis [42] but the present
discussion will be limited to proteinaceous mediators such as
cytokines and homeostatic enzymes as these are fundamental
in driving immune-inflammatory responses and have been
the subject of considerable study in periodontal research
[36, 43]. A simplified scheme for initiation and progression
of periodontitis is presented in Figure 1. The processes
and interactions illustrated in Figure 1 occur naturally in
healthy individuals in response to resident commensal oral
microflora and this “low-grade inflammation,” although not
detectable at the clinical level, is protective in nature, serving
to prevent the entry of bacteria and their products into the
oral tissues [1, 36]. An ecological shift in the plaque biofilm
microbiota in which pathological bacterial species begin to
dominate triggers enhanced immune responses which may
persist leading to dysregulated and nonresolving chronic
inflammation and hence periodontitis [1].
Epidemiological studies established that, in a homoge-
nous population with even plaque distribution and oral
hygiene practices, periodontal disease experience is not
evenly distributed [44]. Furthermore, it is a common clinical
observation that some patients do not develop periodontitis
despite poor oral hygiene and others who have good oral
hygiene practices (and good general health) occasionally
suffer severe disease. Formal clinical studies reveal that the
extent of inflammation does indeed vary among individuals
for a given dental plaque challenge andhas led to the assertion
that secondary factors modify periodontitis susceptibility
[45]. The dogma is that individuals who are susceptible
to periodontitis mount an excessive, dysregulated immune
response to plaque bacteria leading to tissue breakdown;
individual susceptibility is determined by complex interplay
between secondary factors such as genetic and epigenetic
elements, age, gender, smoking, and systemic health which
all influence the immune response [2, 36]. However, we have
not, as yet, fully characterised quantifiable analytes which
reflect these interacting factors and which allow us to identify
susceptible individuals before they develop periodontitis and
that is one of the clear goals of biomarker research.
2.2. Cytokines and Periodontitis. The biochemical pathways
leading to cytokine secretion during the development of peri-
odontitis involve signalling via the interaction of microbe-
associated molecular patterns (MAMPS, e.g., LPS, DNA,
fimbriae, etc.) and pattern recognition receptors (PRR, e.g.,
Toll-like receptors (TLR) and NOD-like receptors (NLR))
(Figure 1) which are active on a wide range of cells in
periodontal tissues and infiltrating leukocytes [1, 46, 47].
Although the MAMPs are diverse, they lead to the activa-
tion of canonical intracellular signalling pathways, enhanced
function of proinflammatory transcription factors such as
the AP-1 and NF-𝜅B complexes with consequent effects
on cell phenotype and in particular enhanced cytokine
secretion (e.g., IL-8, IL-1𝛽), and altered cell surface adhesion
molecule expression (e.g., E-selectin, ICAMs) which in turn
modify responsiveness, adhesion, and hence immune cell
diapedesis [1, 46]. Further innate effector mechanisms, such
as vascular changes, neutrophil chemotaxis, and function, as
well as the secretion of antimicrobial peptides by neutrophils
and epithelial cells, are initiated by the evolving cytokine
response (Figure 1). Cytokines also activate adaptive immune
responses by stimulating antigen-presenting cells (APCs),
such as dendritic cells, Langerhans cells, and macrophages
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Figure 1: Schematic to illustrate the pathogenesis of periodontitis.The dental plaque biofilm is complex, dynamic, and variable; it is subject to
quantitative and qualitative ecological shifts in response to changes in the local environment (e.g., pH changes), changes in localised immune
regulation, and extrinsic factors such as smoking. Bacteria in dental plaque signal the local tissue cells and immune cells via intrinsic and
secretedmicrobe-associatedmolecular patterns (MAMPs) such as lipopolysaccharide (LPS) and specific antigens (e.g., fimbrial proteins).The
healthy periodontium is maintained by an effective innate response to a commensal (nonpathogenic) microflora in dental plaque which is
restricted to the gingival/plaquemargin and inwhich neutrophils play a pivotal role regulated by low levels of cytokines such as IL-1𝛽 and IL-8.
An ecological shift in dental plaque towards amore pathogenicmicroflora dominated by species such as Porphyromonas gingivalis,Treponema
denticola, and Tannerella forsythia leads to an enhanced immune response through enhanced stimulation of cytokine responses from a wide
range of periodontal and immune cells. The development of periodontitis is driven by an exaggerated activation of intrinsic periodontal
cells, a heightened primary and thereafter secondary cytokine response leading to activation of innate effector responses and in particular
recruitment and activation of neutrophils (in response to elevated IL-1𝛽 and IL-8) and osteoclasts (in response to RANKL). Enhanced local
activity of neutrophils in the periodontium is reflected by increased levels ofMMP-8 (neutrophil collagenase),MMP-9 (neutrophil gelatinase),
and 𝛽-glucuronidase among other enzymes. Activated macrophages and T- and B-lymphocytes may also contribute to the cytokine milieu
through secretion of TNF-𝛼, IL-12, IL-17, and IL-18 and the balance of these proinflammatory cytokines with immunosuppressive mediators
such as IL-10 and TGF-𝛽 may be an important determinant of disease progression. Persistence of this proinflammatory response, coupled
with aberrant resolution, leads to tissue destruction characteristic of periodontitis which involves loss of the soft connective tissues of the
periodontium (lamina propria of the gingiva and the periodontal ligament) and alveolar bone which eventually leads to compromised tooth
function. The presentation and progress of periodontitis are influenced by a number of secondary factors such as age, smoking, coexisting
metabolic disorders (e.g., diabetes, obesity), and genetic susceptibility.
and regulate development of functionally diverse antigen-
specific T-cell subsets once naive T-cells have been activated
by APCs [36, 39]. Thus, T-cell subsets regulate antibody pro-
duction by B-cells (TH
2
cells), cell killing by T-cells and NK
cells (TH
1
cells) as well as enhancing (TH
17
cells) or suppress-
ing (Treg cells) immune functionality [39]. Histologically, T-
cells and plasma cells are prominent elements of the leukocyte
infiltrate at later stages of the developing periodontal lesion
[36, 38]. Immune cell activation is sustained by autocrine
and paracrine loops and the evolving cytokine profile (the
nature of which is dependent on the tissue milieu) serves
to amplify, broadcast, diversify, and refine immune regula-
tion (Figure 1). Persistence of pathogenic microbiota within
the plaque biofilm however leads to an increasingly active
proinflammatory cytokine response in the periodontium and
progression of the periodontal lesion [36]. Epithelial cell
proliferation in the periodontium is a prominent histological
feature of periodontitis progression and serves to increase the
barrier function of the epithelial tissues of the periodontium
[47]. However, gingival fibroblasts are lost (by apoptosis)
as the leukocyte infiltrate increases and MMPs (mostly
from infiltrating neutrophils) increase collagen degradation
causing connective tissue destruction including loss of the
periodontal ligament (PDL) which normally serves to attach
the tooth to the periodontium. In the advanced lesion,
osteoclasts are recruited and activated leading to alveolar
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bone recession. Loss of soft (PDL and gingival connective
tissue) and hard (alveolar bone) tissue leads to the loose teeth
(and eventually tooth loss) periodontal tissues, characteristic
of periodontitis [40].
There is substantial evidence for a key role of numer-
ous cytokines in the initiation and regulation of immune
responses in periodontitis, and, critically, in mediating tissue
destruction (mainly through activation of host MMPs) [36,
46]. A consensus paper of The 7th European Workshop on
Periodontal Disease recently highlighted IL-1𝛽, TNF-𝛼, IL-
6, and receptor activator of nuclear factor kappa-B ligand
(RANKL) as being the cytokines for which there is the most
substantial evidence for having a central role in cytokine
networks in periodontal diseases [48].
IL-1𝛽 is produced by a wide range of periodontal tissues
and immune cells and, as such, is considered to have multiple
roles in innate and adaptive immune responses to plaque bac-
teria which feature in the pathogenesis of periodontitis [49].
IL-1𝛽 acts (often in synergywith TNF-𝛼 and prostaglandin E
2
(PGE
2
)) to induce many of the vascular changes associated
with inflammation and in particular to regulate neutrophil
emigration from the circulation into the periodontium. In
adaptive immunity, IL-1𝛽 stimulates antigen presentation by
APCs and influences T-cell development and phenotype.
Studies of the expression of IL-1𝛽, TNF-𝛼, and PGE
2
in oral
fluids and periodontal tissues in periodontal disease endorse
the important role of these mediators in pathogenesis and,
critically, this is supported by the results of investigations of
their effect in animal models (including key studies using
cytokine antagonists) [49, 50]. Thus, IL-1𝛽, TNF-𝛼, and
PGE
2
will all activate osteoclast activity, MMP secretion, and
alveolar bone resorption in chronic periodontitis.
IL-6 is secreted by a wide range of cells in the peri-
odontium, probably as a secondary response to IL-1𝛽 and
TNF-𝛼 activity. IL-6 is important in regulation, development,
proliferation, and activity of key immune cells (B-cells, T-cells
and monocytes) as well as osteoclasts (which develop from
the monocyte lineage) [36, 47]. lL-6 is a powerful stimulator
of fibroblastMMP secretion and is likely a key cytokine in the
propagation of the inflammatory response to plaque bacteria
at a number of levels [51].
Alveolar bone loss is a critical feature of disease pro-
gression in periodontitis and there is an increasing recog-
nition of the important regulatory interactions between
bone metabolism and inflammation [24, 52, 53]. RANKL
stimulates bone resorption and is upregulated by IL-1𝛽 and
IL-6 among other cytokines; thus the ratio of RANKL and
its natural antagonist osteoprotegerin (OPG) is a particularly
important factor in determining bone cell resorption and
turnover [52, 54] and this ratio is elevated in periodontitis
[24, 36].
2.3. Matrix Metalloproteinases and Periodontitis. There are
some 23 MMPs in man which comprise a structurally
related but genetically distinct superfamily of zinc-dependent
endoproteases [55]. MMPs are categorised according to their
perceived main substrate but it is now clear that MMPS
have complex and overlapping enzymatic activities and will
digest a wide variety of peptide sequences, found in a number
of protein substrates and few of which are targets unique
to individual MMPs [56–58]. MMPs are synthesised by
the majority of cell types in the periodontium including
fibroblasts, keratinocytes, endothelial cells, and osteoclasts
as well as infiltrating leukocytes including neutrophils and
macrophages [58]. MMPs have a wide range of fundamental
physiological roles which include tissue development, home-
ostasis, and repair as well as roles in immune responses,
including antigen processing and presentation in addition
to cell migration [57]. MMPs are regulated at a number of
levels including cytokine and growth factor-regulated gene
transcription, processing, and activation (by other proteases
in situ) [56, 57]. Inhibition of MMP activity through the
formation of complexes with other molecules such as tissue
inhibitors matrix-metalloproteinases (TIMPs) and serum
glycoproteins such as 𝛼
2
macroglobulin is another regulatory
mechanism and balance between the levels of MMPs and
these natural inhibitors is thought to be a crucial determinant
of overall MMP activity [56, 57, 59]. In periodontal disease
MMP synthesis and secretion is dysregulated, the balance
of MMPs and TIMPs is altered, and the levels of neutrophil
MMPs such as MMP-8 and MMP-9 are elevated, likely due
to greatly increased numbers of neutrophils emigrating into
the periodontitis lesion and the GCF as the result of the
inflammatory process [60]. In particular, it is established that
the levels ofMMP-8 inGCF correlate closely with the severity
of periodontal disease and that levels decline in parallel to
successful periodontal therapy [16, 61, 62]. The finding that
subantimicrobial disease of the doxycycline inhibits MMP-
8 and can be successfully used as an adjunct therapy for
periodontitis further endorses the importance of MMP-8 in
periodontitis [63, 64].
2.4. The Spectrum of Signalling and Effector Molecules in
Periodontitis. Collectively, we have much information on the
role of a wide range of other host regulatory and effector
molecules in the initiation, progression, and resolution of
periodontitis although the sum total of information on
individual mediators is limited [24, 36]. IL-17 is derived
from TH
17
cells and serves to reinforce innate responses
in periodontal cells through synergising with MAMPs to
enhance IL-1𝛽 secretion [65]. Conversely, IL-10 and trans-
forming growth factor-𝛽 (TGF-𝛽), for example, derived
from Treg cells, can modify innate and adaptive immune
responses in periodontitis in a variety of ways, often, but
not always, inhibiting immune responses [36, 66]. Numerous
chemokines (such as CCL3 (MIP-1𝛼), CXCL8 (IL-8), and
CXCL10) are secreted by periodontal cells in response to
primary proinflammatory mediators such as IL-1𝛽 and have
been identified as having potential roles in periodontal patho-
genesis and in particular in the recruitment and migration
of neutrophils and other leukocytes to the periodontium [36,
67]. A number of growth factors are important in periodontal
pathogenesis as they regulate connective tissue homeostasis
and repair and can synergise with and be upregulated by
proinflammatory cytokines [47]. Although there is some
information on potential roles of individual growth factors
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such as hepatocyte growth factor (HGF), platelet-derived
growth factor (PDGF), and TGF-𝛽 in periodontitis [68–70]
given the considerable number of structural isoforms and the
great functional pleiotropy of human growth factor families
our knowledge of the role of these mediators is still far from
complete.
The periodontium is an intricate tissue in which hard
and soft tissues are uniquely juxtaposed and which comprises
numerous different cell types. The periodontium is exposed
to a complex, variable, and chronic bacterial challenge, in
which a chronic inflammatory process is often established.
Thus, it is unsurprising that the profile ofmolecularmediators
is similarly complex, dynamic, and variable. Also, in recent
years it has become apparent that although we have a
much improved understanding of fundamental cellular and
molecular processes relevant to periodontal pathogenesis,
these are often “snapshots” of individual pathways and
our understanding of how these pathways are integrated
and how they map to the initiation and progression of
periodontitis and, critically, the possible resolution of this
disorder is limited [36]. Thus, although it is recognised
that collectively these mediators constitute a complex system
which has the functional properties of a network rather than
existing as many parallel, linear pathways, we have yet to
understand how these function in immune responses and
immune-mediated disease. A property of complex networks
of interacting molecular elements is that changes in the levels
of individual elements do not necessarily have predictable
effects on the functionality of the network and that there
may be new, emergent properties not obvious from the study
of individual molecules in isolation [71]. Therefore, one of
the major barriers to our exploitation of this knowledge
(e.g., in the identification of key biomarkers) is gaining a
holistic understanding of the relative roles of the vast array
of known mediators in the pathogenesis of periodontitis and
currently, in terms of biomarker identification, we still rely
on information from “candidate” mediator studies and the
literature is dominated by many studies on a limited number
of these candidate markers such as IL-1𝛽, OPG, and MMP-8.
3. Protein Biomarkers of Periodontitis:
Candidate Protein Studies
3.1. Cross-Sectional Clinical Studies. Clinical studies of GCF
and saliva have identified a number of promising individual
mediators which are associated with periodontal disease and
correlated with clinical measurements of periodontitis, and
whose levels change in parallel with the clinical course of
the disease and in response to treatment [24, 29, 72]. The
majority of studies have been “cross-sectional” in design and
have simply compared mean levels of mediators in groups of
periodontitis patients with those found in healthy volunteers.
These studies are thus attempting to identify “association”
with periodontitis and therefore whether or not the potential
biomarker fulfills the requirement of being “discriminatory.”
Also, there are substantial confirmatory studies for only a
limited number of these candidate biomarkers; therefore
few such biomarkers can be described as “robust.” Salivary
mediators analysed in these cross-sectional studies and an
assessment of the possible role of these proteins as biomarkers
for periodontitis are presented in Figure 2.
Evidence from studies of GCF suggests that cytokines
likely form a substantial and measurable element of oral
fluids [24]. There is a well-established association between
elevated levels of IL-1𝛽 in GCF and periodontitis [24, 49].
There is strong evidence to suggest that salivary IL-1𝛽 is a
good biomarker of periodontitis in as much as measurement
of IL-1𝛽 can discriminate periodontitis samples from those
provided by healthy volunteers [73–79] but this finding has
not been replicated in all studies [80–82]. Also, one study of
some 98 periodontitis patients revealed a positive correlation
between levels of salivary IL-1𝛽 and the extent of alveolar
bone loss [83].
Studies of salivary TNF-𝛼 levels have failed to provide
evidence of association with periodontitis often because
the levels of TNF-𝛼 in saliva are very low or nonexistent
[75, 76, 78, 79, 81, 82, 84]; although one study did report
significantly elevated levels of TNF-𝛼 in periodontitis patients
as compared to healthy controls, the actual levels of TNF-𝛼
were very low (<4.3 pg/mL) [85].
The majority of studies of salivary IL-6 demonstrate no
association with periodontitis [75, 78, 81, 82]. In contrast,
there are 3 reports of significantly elevated salivary IL-6
levels in periodontitis [79, 86, 87]. However, analysis of
salivary GM-CSF, IL-2, IL-3, IL-4, IL-5, IL-10, IL-12, and IFN-
𝛾 revealed no significant associations with periodontitis [81,
82, 88] although there is a single report of elevated salivary
IL-4 and significantly lower salivary IL-17 in periodontitis
[87]. Interestingly, IFN𝛼 levels have been found significantly
elevated in the healthy individuals as compared to patients
with periodontitis [79].
Although there is a paucity of data on salivary
chemokines in periodontitis, 2 studies have indicated that
salivary CCL3 (MIP-1𝛼) levels are significantly associated
with periodontitis [89, 90]. There is, as yet, no evidence that
CXCL8 (IL-8) has a potential as a biomarker for periodontitis
[78, 81].
Interestingly, there is evidence from 2 independent stud-
ies that levels of salivary soluble CD14 (sCD14) are elevated
in periodontitis [87, 91]; sCD14 mediates the action of LPS
andmay promote bacterial invasion of host cells in periodon-
titis [92, 93]. Also, although salivary sTLR2 augments IL-8
(CXCL8) production inmonocytes [94], there is evidence for
diminished levels of sTLR2 in periodontitis saliva [87].
There is an emerging interest in a number of cytokines
such as osteocalcin, RANKL, and OPG which are regulators
of bone cell activity and, as such, mediate bone loss char-
acteristic of periodontitis [24, 95]. However, the results of
analysis for potential associations of salivary levels of these
cytokines and periodontitis have been variable. Thus, one
study failed to find significant differences between RANKL
levels in periodontitis as compared to controls [85] although
a more recent report presented data to the contrary, showing
elevated levels of RANKL in saliva from periodontitis patient
[96]. Also, significantly lower levels of OPG in periodontitis
as compared to controls have been reported [82, 96] but other
studies found no evidence for such a correlation [73, 86, 90].
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Figure 2: The possible role of salivary proteins as biomarkers of periodontitis. “Robust” biomarkers are defined as those salivary proteins
which have been shown to discriminate between periodontitis and oral health in at least 3 cross-sectional studies (with comparatively little or
no published evidence to the contrary) and for which there may be supporting evidence from longitudinal studies investigating the natural
course of periodontitis and/or the effects of treatment on biomarker levels. “Potential” biomarkers are identified using identical criteria to
“robust” biomarkers with the exception that there are 2 replicated cross-sectional studies showing disease discrimination in addition to
possible supporting evidence from longitudinal studies but for which theremay be limited contradictory studies. It is accepted that the entries
in the “robust” and “potential” categories may be interchangeable depending on the existence of further studies which remain unpublished
for commercial reasons. “Uncertain” biomarkers are proteins for which there are only single studies showing discrimination of periodontitis
or for which there are several studies from which the evidence is contradictory. “Unlikely” biomarkers are those proteins for which there are
3 or more studies which fail to provide evidence for an association with periodontitis in the absence of any evidence to the contrary. For a
more detailed description of the published research studies and the putative role of these proteins in periodontitis see the main body of the
text.
The data for association of both salivary osteonectin and
osteocalcin (both of which have a role in bone metabolism
[97, 98]) with periodontitis are similarly inconsistent [99–
103].
A number of studies of salivary biomarkers for periodon-
tal disease have used candidate molecules identified through
their established use as systemic markers of inflammatory
disease in general medicine. For example, calprotectin is
a neutrophil protein which is considered to be a marker
of inflammation [104] and is increased in the saliva of
periodontitis patients [82] as is procalcitonin, which is also
a marker of systemic inflammation [105, 106]. Similarly,
although 2 studies from the same group suggest that reduced
levels of the acute phase protein C-reactive protein (CRP) in
saliva are associated with periodontitis [84, 107], data from
other studies are not consistent with this finding [80, 108].
Studies of salivary levels of the complement components C3
and C4 have revealed an association of periodontitis with
lower levels of C3 found in saliva as compared to healthy
controls [84, 107]. Lactate dehydrogenase (LDH), alkaline
phosphatase (ALP), aspartate aminotransferase (AST), and
alanine aminotransferase (ALT) are markers of cellular dam-
age and inflammation; there is evidence for an association
between salivary levels of all these mediators and periodonti-
tis [109–114] with the exception of one study which reported
no associationwithALP, AST, orALT [111] and another which
failed to reproduce significant association with salivary LDH
[75].
𝛽-Glucuronidase is an enzyme found in neutrophil lyso-
somes where it has a role in the digestion of proteoglycans.
𝛽-Glucuronidase levels in saliva are a marker of neutrophil
influx into GCF and salivary levels of this enzyme correlate
with the severity of periodontitis [72, 115]. Also, measure-
ments of salivary glutathione peroxidase, as a marker of
neutrophil antioxidant capacity, show that the levels of this
enzyme are significantly elevated in periodontitis [102, 116].
Saliva contains abundant antibacterial proteins such as
lysozyme, and cystatins, but there is only a single report of sig-
nificantly reduced levels of salivary cystatins in periodontitis
[117] and the results from studies of salivary lysozyme have
been contradictory [78, 117, 118].
Growth factors have diverse functions which overlap and
contribute to immune responses but although elevated levels
of growth factors including TGF-𝛽, epidermal growth factor
(EGF), and vascular endothelial growth factor (VEGF) have
been reported in the GCF of patients with periodontitis [95],
there is a dearth of information about salivary growth fac-
tors and periodontitis. Exceptionally, 3 independent studies
demonstrated significant association of salivary HGF with
periodontitis [119–122] which is consistent with similar data
analysing GCF [123]. In terms of function, HGF is known
to be involved in dental development [124] but, significantly,
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HGF is secreted by gingival fibroblasts and HGF secretion
is regulated by cytokines and bacterial products; it has
been hypothesised that HGF may mediate epithelial apical
migration in periodontitis [124, 125].
Data from analysis of MMP in saliva in periodontitis
are consistent with the findings from studies of GCF [24].
Nonetheless, studies of GCF are more extensive and there is
a requirement, given the advantages of salivary analysis, to
replicate these studies using saliva collection. In particular
numerous more longitudinal studies have been performed
and analysis of GCF levels of other members of the MMP
superfamily (e.g., MMP-7, MMP-25) has identified a wider
range of candidate biomarkers [24]. That neutrophil collage-
nase (MMP-8) activity in saliva is elevated in periodontitis
patients as compared to healthy volunteers and it correlates
with clinical measures of periodontitis is well-established by
the results of numerous studies [73, 76, 78, 79, 82, 86, 102, 126–
134]. Significantly, total collagenase activity in health is in
the form of the inactive procollagenase as compared to a
preponderance of activated collagenase in periodontitis saliva
[128]. Furthermore, with the exception of a single study
[130], TIMP-1 concentration has been found to be higher in
saliva from healthy individuals as compared to periodontitis
patients [128, 134, 135]. However, there is no evidence for an
association of salivaryMMP-1 (fibroblast collagenase),MMP-
3 (stromelysin-1), or MMP-14 (a membrane-typeMMP) with
periodontitis [130, 134]. A key question is whether or not a
particular biomarker for periodontitis cannot only identify
the presence of periodontal inflammation but also whether
or not it is able to determine the extent of inflammation; that
is can the marker distinguish periodontitis from gingivitis?
In this regard, MMP-8 seems to be a better biomarker of
periodontitis than other markers such as IL-1𝛽 [78].
Salivary gelatinases (MMP-2 and MMP-9) and elastase
have been found to be significantly elevated in periodontitis
patients as compared to controls [82, 108, 129, 135, 136]
although there are reports of no differences between disease
and control sampleswith respect to salivaryMMP-9 [130] and
elastase [75].
Collagen matrix degradation by proteases such as MMPs
leads to the release of fragments of collagen into the cir-
culation; these peptides can be assayed as a measure of
bone resorption in periodontitis [95]. One such peptide
is C-telopeptide pyridinoline cross-links of type-1 collagen
(ICTP), but although ICTP is elevated in GCF from peri-
odontitis patients [95] and has been found to be elevated in
periodontitis and associated with clinical measures of peri-
odontitis [103, 134, 137], several other independent studies
have failed to detect salivary ICTP in saliva from themajority
of periodontitis patients [82, 83, 85, 90]. Nevertheless, other
peptidemarkers of bone loss and osteoclast activity including
C-terminal peptide of type 1 collagen (CTX-1), N-terminal
peptide of type 1 collagen (NTX-1), and tartrate-resistant
acid phosphatase serum type 5b (TRACP 5b) correlate with
clinical periodontitis and may have promise as salivary
biomarkers although these markers are not found universally
in saliva samples [102, 138].
Aggressive (acute) periodontitis is a form of periodontal
disease associated with rapid loss of alveolar bone and
gingival attachment and as such has a distinct presentation
and clinical course to the more common chronic periodon-
titis described above [139]. It is plausible that appropriate
biomarkers may be employed to distinguish between these
related disorders. For example, antibodies to Aggregatibac-
ter actinomycetemcomitans (a periodontal pathogen often
associated with aggressive periodontitis) and Porphyromonas
gingivalis are thought to have a key role in protective
immunity in aggressive periodontitis [140] but although
these antibodies are indeed found in saliva their presence
is not specific to aggressive periodontitis [141, 142]. A very
limited number of studies (of comparatively few patients)
have directly compared levels of mediators in aggressive
periodontitis and chronic periodontitis [91, 127, 143]; with the
exception of one study which reported elevated cathepsin C
activity in the saliva of aggressive periodontitis patients [143]
none of these studies have identified biomarkers whichmight
be potentially specific for aggressive periodontitis. Although
there is a real need for larger studies, establishing specific
protein biomarkersmay be challenging as there is no evidence
for significant differences in the immunopathogenesis of
these two clinical manifestations of periodontitis [139].
3.2. Longitudinal Clinical Studies. Although many markers
are discriminatory, that is, exhibit significant alterations in
periodontitis and robust, that is, have been found to be
discriminatory in more than 3 independent studies, their
clinical utility remains uncertain. Many studies outlined
above have quantitatively correlated mediator levels with
clinical measurements of periodontitis (e.g., bleeding on
probing, clinical attachment loss, and pocket depth) although
this data has not always been presented. However, it is unclear
whether or not these measurements reflect current disease
activity or are the result of historical disease progression
or whether or not the levels of many candidate biomarkers
significantly associated with periodontitis in cross-sectional
studies accurately reflect the likely path of disease progression
and response to treatment. Although a number of longitudi-
nal studies have recorded changes in GCF levels of MMPs in
parallel with the clinical course of periodontitis, the data for
salivary analysis is rather limited and is the result of studies
using clinical protocols which are very variable making
meaningful comparisons between studies difficult to achieve.
Therefore, the need for more substantial clinical studies very
much still exists [24].
In broad terms, published longitudinal studies of salivary
mediators in periodontitis may be categorised as studies of
levels during the natural progression of the periodontitis in
patients without therapeutic or healthcare interventions and
studies of the effects of particular active healthcare regimens.
In a prospective cohort study, 219 unselected subjects were
monitored over a 4-year period, during which time they did
not undergo any dental treatment and changes in periodontal
pocket probing depth (as a measure of periodontitis) as
compared to levels of salivary biomarkers and lifestyle factors;
a multiple logistic model revealed that disease progression
related to smoking habit and not the levels of any of some 9
protein biomarkers (IL-1𝛽, MMP-8, MMP-9, lactoferrin, IgA,
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albumin, AST, LDH, and ALP) [144]. Significantly, levels of
salivary lactoferrin, AST, and LDH were reduced in smokers,
a finding consistent with the known immunosuppressive
effect of cigarette smoke [144, 145]. In a longitudinal case-
control study salivary biomarkers including osteonectin,
HGF, IL-1𝛽, IFN-𝛾, TNF-𝛼, IL-4, IL-6, IL-8, and ICTP were
measured in 40 subjects who exhibited significant alveolar
bone loss over a 5-year follow-up period as well as in 40
age-matched subjects with no bone loss [120]. The results
demonstrated a negative association between the extent of
alveolar bone loss over the 5-year period and levels of
salivary osteonectin and a positive association of bone loss
with both IL-1𝛽 and HGF suggesting that measurement of
these mediators at baseline may have a predictive value in
monitoring periodontitis [120]. Another prospective cohort
study found that levels of salivary MIP-1𝛼 (CCL3) and IL-
1𝛽 (among 19 other mediators that were assayed) were both
significantly elevated in 7 subjects with localised aggressive
periodontitis as compared to 41 individuals who stayed
healthy [89].Moreover, the levels ofMIP-1𝛼 in salivawere ele-
vated prior to radiographic detection of bone loss suggesting
that this mediator may be predictive of longitudinal disease
progression in periodontitis and analysis of covariance sug-
gested that salivaryMIP-1𝛼 had the strongest correlationwith
periodontal destruction [89]. Although both salivary MIP-
1𝛼 and IL-1𝛽 were elevated in subjects with periodontitis in
this study, the level of MIP-1𝛼 is considered to be a more
sensitive biomarker for periodontitis as levels of salivary
MIP-1𝛼 were increased 50-fold in contrast to the mere 5-
fold elevation of IL-1𝛽 [89]. Also, IL-1𝛽 is regarded as a
marker of inflammation as well as tissue destruction andmay
not therefore be directly predictive of disease progression in
periodontitis [89, 146].There is, therefore, some evidence that
certain biomarkers reflect disease progression in untreated
patients but smoking habit clearly influences biomarker
status [144] and, unfortunately, smoking data has not been
alluded to in all studies [89, 120].
Numerous more studies have investigated the effects
of various treatment regimens, including nonsurgical and
surgical approaches, on salivary biomarkers in periodontitis.
However, the treatment regimens applied have differed con-
siderably between studies and, unfortunately, there are insuf-
ficient data to compare the effects of particular periodontal
therapies on individual biomarkers. Nonetheless, a common
finding is a decline in biomarker level in parallel with
improvement in clinical measures of periodontitis. Thus, a
significant reduction for active collagenase after surgical and
nonsurgical treatment in both localised juvenile periodontitis
and adult periodontitis patients has been recorded [60, 127].
Comparison of the behaviour of salivary proteases (not
including collagenase) and glycosidases in patients treated for
periodontitis revealed that although the levels of both types
of enzymes declined as a result of treatment, they did not
do so simultaneously [147]. Two smaller studies of the effect
of periodontal treatment on salivary antibacterial proteins
have yielded inconsistent data [148, 149]. There is, as yet,
no evidence that salivary glutathione peroxidase is altered
by treatment in periodontal disease [150]. However, systemic
markers of inflammation (AST, ALT, and LDH) do decline
after nonsurgical treatment for periodontitis, at least over
a 4-week period [151]. A modest study of 20 periodontitis
patients and 20 controls demonstrated that IL-4 decreased
significantly and sTLR2 increased significantly following
such treatment [87]. In a study of 39 postmenopausal women,
salivary osteocalcin was shown to be inversely related to
decrease in clinical measures of periodontitis [99]. Salivary
MMP-8 (but not MMP-9) levels were found to be reduced
after nonsurgical treatment for periodontitis in 33 patients
but, interestingly, not if adjunctive doxycycline treatment was
included [152]. Conversely, TIMP-1 increased after nonsur-
gical treatment with adjunct doxycycline treatment but not
after nonsurgical treatment alone [152].
A key recent study reported the longitudinal clinical
investigation of periodontitis in parallel to measurement of
a panel of potential biomarkers, a cohort of 100 volunteers
[153]. Significantly, the study consisted of a 6-monthmonitor-
ing phase, during which no treatment was provided. During
the monitoring phase there were no changes in clinical
periodontitis in the volunteers and the levels of biomarkers
as compared to baseline did not change significantly. This
was followed by provision of appropriate treatment, followed
by a 6-month “disease-recovery” phase during which disease
recovery and progression were monitored [153]. It was found
that the levels of MMP-8, MMP-9, OPG, and IL-1𝛽 declined
significantly after treatment in volunteers with moderate to
severe periodontitis. In a case-controlled study of some 68
patients with periodontitis, biomarkers were serially analysed
throughout the course of 28 weeks when 33 patients received
oral hygiene instruction (OHI) only and the remaining
35 patients had nonsurgical treatment in addition to OHI
[146]. Periodontitis improved in both groups in parallel with
a significant reduction in salivary MMP-8 levels. Detailed
analyses revealed that levels of salivary OPG and MIP-1𝛼, in
addition to MMP-8, were able to discriminate patients who
responded to treatment from those who did not. However,
IL-1𝛽 and MMP-8 levels decreased significantly only in
the group receiving nonsurgical treatment in addition to
OHI (as compared to OHI alone); this treatment group
also exhibited the greatest reduction in clinical measures
of periodontal disease, suggesting that these markers most
accurately reflected clinical changes in periodontitis [146].
Receiver-operator characteristic analysis showed that MMP-
8 was the best biomarker to reflect response to therapy [146].
Given the complexity of the disease pathogenesis and
progression and the recognised interindividual differences
in disease experiences it is likely that multiple biomarkers
will be required in order to provide full diagnostic efficacy
[142, 153]. The concept of “biomarker signatures” in which
multiple rather than individual markers provide more robust
association with periodontitis has been endorsed by the work
of Ebersole et al. [79]; in a study of 30 healthy adults and 50
patients with periodontitis, salivary IL-1𝛽, IL-6, and MMP-
8 were all significantly elevated in the patient group and
receiver-operator characteristic analysis indicated that all 3
mediators had sensitivity and specificity values in the range
80–97% and positive predictive values of >90% [79]. These
authors have previously described substantial intraindividual
“random” variation in the salivary levels of these mediators
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in healthy individuals [154] but, despite this, simultaneous
analysis of a combination of analytes (IL-1𝛽, IL-6, andMMP-
8) clearly has a high capacity to distinguish periodontitis
patients from healthy individuals [79].
It is possible that different tests will be applicable to
screening for disease susceptibility as compared to those
required for monitoring of therapy and treatment selection
[21]. Interestingly the power to predict differences between
periodontal disease categories (moderate to severe periodon-
titis as compared to mild periodontitis and gingivitis) was
increased when measures of salivary MMP-8 were combined
with those of MMP-9, OPG, and calprotectin and quantifi-
cation of periodontal pathogens such as P. gingivalis and
Treponema denticola in dental plaque [82]. Also, a decline
in the levels of MMP-8, MMP-9, OPG, and IL-1𝛽 occurred
in parallel with changes in the levels of several periodontal
pathogens in dental plaque [153]. Using hierarchical clus-
tering analysis the authors found that the combined levels
of biomarkers (both molecular and bacterial) successfully
predicted progression of periodontitis and disease stability
during the recovery phase for the majority of cases. Parallel
analysis of mediators in serum samples suggested that this
approach was not sensitive to the clinical course of peri-
odontitis in agreement with previous findings [155, 156]. This
approach supports the concept of a “biological signature”
of multiple distinct analytes in saliva encompassing several
different elements of host-pathogen interactions in periodon-
titis acting as biomarkers [79, 82, 153].
4. Protein Biomarkers of Periodontitis:
Proteomic Studies
The majority of studies characterising salivary protein
biomarkers in periodontitis published thus far have been
based on markers derived from pre-existing information on
themolecular pathogenesis of periodontitis; there needs to be
a more open, unbiased approach to biomarker identification
in periodontitis. Thus, high throughput proteomics holds
promise for disease-associated biomarker identification [157]
and substantial progress has been made in the proteomic
analysis of saliva through a combination of sophisticated
approaches to protein separation and advances in mass
spectrometry technology [157, 158]. The salivary proteome
has now been identified; it contains some 1166 proteins
[159] and proteomic studies confirm the commonality of the
salivary proteome and plasma proteins [159, 160]. Proteomic
approaches have already identified salivary biomarkers of
both Sjogren’s syndrome and oral cancer [19, 161, 162].
A number of preliminary studies investigating the pro-
teomic profile of saliva in periodontitis using a combination
of 2D electrophoresis and mass spectrometry have been
published [163–165]. Although this approach determines the
salivary protein profile in an unbiased analysis, the approach
is only sensitive enough to detect proteins with a relatively
high abundance and many mediators, for example, cytokines
and MMPs, are not in sufficiently high concentrations to
be detected [164, 166]. Thus, in a comparative study of
salivary proteins from 5 patients with generalised aggressive
periodontitis (GAgP) and 5 healthy patients, some 11 proteins
were found to be altered in the GAgP patients; these included
some high abundance proteins already known to be asso-
ciated with inflammation including 𝛼-amylase, lactoferrin,
IgG2, IgA2, and albumin [163]. Increased vitamin-D binding
protein was also found to be associated with localized aggres-
sive periodontitis (LAgp) for the first time [163]. Similar
changes in 𝛼-amylase, Ig heavy chain, and albumin (along
with decreased cystatin levels) in saliva from patients with
chronic periodontitis and gingivitis have also been noted
in independent proteomic studies [165, 167]. Other proteins
exhibited decreased expression in GAgP: these included
elongation factor 2, 14-3-3 sigma, lactotransferrin, and short
palate, lung, and nasal epithelium carcinoma associated
protein 2 (PLUNC2) [163]. PLUNC2 (also known as parotid
secretory protein) was also found to be decreased in the saliva
of patients with active periodontitis as compared to saliva
from the same patients after treatment [164]. Furthermore,
three independent proteomic studies have confirmed the
presence of increased levels in periodontitis saliva of two
of the S100 family of calcium binding proteins which have
known roles in regulation of inflammation [163, 166, 168].
A recent study has applied a highly sensitive liquid chro-
matography/mass spectrometry protocol (which obviates the
need for 2D gel electrophoresis) to the analysis of the salivary
proteome in 20 patients with periodontitis as compared to
saliva from 20 healthy volunteers [166]. This study identified
some 20 proteins which were differentially expressed in
periodontitis saliva andmost, includingMMP-8,MMP-9, 𝛼
2
-
macroglobulin, and complement C3, have previously been
identified as potential biomarkers in conventional analysis of
periodontitis saliva [166].The authors note that, in agreement
with other studies using mass spectrometry analysis of
fractionated salivary proteins, only small differences between
the levels of these proteins distinguish periodontitis saliva
from saliva from healthy volunteers [166]. Gene ontology and
pathways analysis for the data from this study reveal that the
differentially expressed mediators are mostly associated with
the acute phase responses and regulation of inflammation
[166]. Although proteomic analyses of this kind provide the
unbiased detection of salivary proteins, issues of sensitivity,
recovery, and processivity remain a hindrance to achieving a
comprehensive global analysis of salivary proteins; however,
new technological developments are addressing these issues
and there is the promise that this approach will deliver
information to enhance candidate protein studies [169].
Developments in bioinformatics will play a key role in
the interrogation of data from proteomic studies, integra-
tion with other global analyses (e.g., transcriptomics and
metabolomics), exploitation of knowledge of complex bio-
chemical and cellular interactions, and ultimately, therefore,
in the identification of salivary biomarkers not obvious from
studies of candidate proteins [170]. A key advance in this
area is the development of the salivomics knowledge database
(SKB) and the salivary proteome knowledge base which
is part of the human salivary proteome project [170, 171].
Salivomics is an emerging discipline which describes the
study of related sets of biological molecules including the
transcriptome, the proteome, and the metabolome in saliva
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and which, it is envisaged, will drive the development of
personalised diagnostic approaches in the dental clinic [170,
171].The SKB contains a data management resource sourcing
salivomics research data which interfaces with other relevant
databases [170, 171].
5. Future Challenges in
Biomarker Identification
Biomarkers must be straightforward to analyse; the readout
should be readily interpretable, and give enhanced informa-
tion such as being able to predict onset, measure activity,
and monitor disease progression (e.g., from gingivitis to
periodontitis or in terms of severity of periodontitis or relapse
after treatment) and there is real promise that a number of the
markers described in the previous section may fulfill these
criteria. However, there are a number of scientific, clinical,
and technological challenges to achieving the successful
clinical application of salivary diagnostics in themanagement
of periodontitis [171].
5.1. Clinical Study Design. Despite our growing knowledge
of the molecular mediators of periodontitis and the advent
of salivomics, there remains a lack of substantial, well-
controlled, clinical studies aimed at characterising the efficacy
of individual biomarkers or combinations in monitoring
periodontitis. In particular, the majority of such studies
published thus far have been conducted on a cross-sectional
basis rather than longitudinal design and another weakness
of many studies is that they are statistically underpowered
and focused on individual mediators [24, 36]. Also, there
is a dearth of studies which have substantially analysed
the relationship of salivary biomarkers with the natural
progression of periodontal disease, for example, in long-term
epidemiological studies or during an experimental gingivitis
model. It is important to note that there are a number of
practical issues which complicate the design and interpre-
tation of such studies. For example, widespread adoption of
uniform definitions of periodontal disease remains an issue
there is subjectivity and variability of definitions employed
and a consensus is required for the design of multicentre
trials, for comparison of different trials, and for the correct
conduct of community and epidemiological studies [172, 173].
Also, it has long been recognised that the progression of
periodontitis is highly variable. Initially, it was thought that
the periodontal lesion progressed in a linear fashion albeit at
a rate variable between individuals [174]. Latterly, the “burst”
or “episodic” hypothesis has emerged to explain the variable
phases of tissue breakdown and repair around individual
tooth sites in periodontitis patients [175]. It is now considered
that these theories of periodontal progression are not mutu-
ally exclusive and that they represent manifestations of the
cyclical destructive inflammation and improvement which
occur longitudinally in individual sites [176].Nonetheless, the
progress of periodontitis and response to treatment remains
complex and highly variable and therefore difficult to predict.
A major issue in clinical studies of periodontal dis-
ease is cigarette smoking which modifies numerous salivary
mediators [144, 145] and strongly influences periodontitis
[14, 177]. Therefore, the inclusion of smokers confounds the
conclusion ofmany studies.Other confounding factorswhich
ideally should be eliminated from such studies include age,
gender, race, and comorbid conditions [146]. A rubric to
integrate the many quantifiable elements which contribute
to periodontal pathogenesis with the complex clinical course
and the changes in biomarkers needs to be developed using
bioinformatics and a systems biology approach; this may
facilitate the provision of more detailed clinically useful
information which will inform a more individualised and
effective clinical management approach [46, 170, 178, 179].
5.2. Salivary Collection Protocols. In addition to a broadening
of the biochemical analysis for biomarker into the realm of
salivomics and more appropriate clinical validation studies
for salivary biomarkers outlined above, there are a number of
practical issues that need to be addressed before this approach
is translated into a bona fide diagnostic test.
In particular, there needs to be a reliable method of
salivary collection; to date, a great variety of approaches have
been used which will impact on the effectiveness of the test
[20, 180]. Variation in salivary flow rates, stimulatory factors,
and gingival inflammation contribute to a variable salivary
composition [28].Themode of collection is also critical; some
studies report the use of stimulated or unstimulated saliva
and the collection of whole saliva or saliva secreted from
individual glands. Also many studies do not record the time
of collection, a relevant factor as many salivary components
exhibit circadian rhythm [20]. Some studies have adopted
an “oral rinse” protocol which is considered to be a fluid
containingGCF fromall the periodontal pockets and thus has
the advantage, like whole saliva, of reflecting disease activity
in the whole mouth rather than individual sites as with GCF
collection [181], whereas whole saliva is collected by a variety
of methods and its content may be affected by the flow rate.
5.3. Biomarker Analysis Technology. The method of analysis
needs to be fit for the purpose. Althoughmost clinical studies
of salivary protein biomarkers have employed conventional
ELISAs, there has been some interest in developing novel
point-of-care (POC) devices which may be used in the
dental clinic and eventually domestically. The real promise
of salivary analysis use is the ability of the patient or
clinician to directly and continuously assess disease status,
progression, and therapeutic efficacy. Sensitive analysis may
even allow presymptomatic diagnosis. Thus, microfluidic
andmicroelectromechanical systems (MEMS) and nanoelec-
trofluidic systems (NEMS) for salivary diagnostics have been
under development for at least the last decade [19]. Multi-
plex analysis is envisioned, perhaps involving simultaneous
detection of different molecular structures such a proteins
and nucleic acids [19]. Microfluidics have the advantage of
using low sample and reagent volumes; microelectronics
facilitate the development of miniaturised chairside and
handheld devices suitable for use in the dental clinical
and home in the absence of specialised laboratory facili-
ties. In combination, they promise to provide simultaneous
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and rapid measurement of multiple biomarkers coupled
with data storage and transmission. Any novel technology
must also have commercial attractiveness [21]. Technological
developments aim to optimise biomarker measurement with
respect to high sensitivity, high specificity, miniaturisation,
high throughput, automation, portability, low cost, high
functionality, measuring multiple disease markers, and sim-
plicity of use. POC devices may also potentially enhance
epidemiological research in remote and impoverished areas
which lack access to laboratory technology and appropriate
sample storage and transport facilities. There are several
examples of POC devices at prototype stage [80, 132, 182];
these devices potentially have greater sensitivity and linearity
than conventional immunoassays. The performance of these
deviceswill be likely dependent on reagents employed and the
lack of appropriate antibodiesmay limit development of some
biomarker assays. For example, some monoclonal antibodies
toMMP-8 preferentially detect activeMMP-8 whereas others
may detect total MMP-8 including the biologically inactive
pro-MMP-8 [181, 183]. Differences in immunoreactivity of
antibodies employed in immunoassays may account for
discrepancies in the results of some of the aforementioned
clinical studies. However, the status of this field remains
uncertain as clearly dissemination of detailed information
is likely limited by commercial sensitivities and intellectual
property restrictions.
5.4. Clinical Adoption. There needs to be an understanding
of the issues relating to acceptance of these novel diagnostic
approaches by dental clinicians and their patients alike. The
derivation of the so-called “value propositions” is likely to be
a useful approach whereby key questions such as feasibility,
diagnostic accuracy, impact on patient management and
outcomes, and also impact on society (including return
on investment issues) are addressed [184]. Patient self-care
in periodontitis is critical to the economically viable and
widespread prevention of severe disease [185]; identification
of biomarkers and development of simplemonitoring devices
may facilitate this.
6. Concluding Remarks
We now have substantial information suggesting that a
limited number of protein biomarkers may be efficacious in
diagnosis and management of periodontitis. These markers
(e.g., MMP-8 and IL-1𝛽) have been identified on the basis
of their known role in disease pathogenesis; there needs to
be an approach to the unbiased selection of markers using
“salavomics” coupled with more substantial, longitudinal,
clinical studies in order to develop this field further. There
is also a need to develop a practical approach to chairside
analysis which will enable the dental clinician to efficiently
and accurately assess periodontitis disease activity. Develop-
ment of effective salivary protein biomarkers for periodontitis
will ultimately require amultidisciplinary approach involving
biological scientists, biotechnologists, engineers, and clini-
cians. If these aims are realised then this will greatly enhance
not only the clinical care of periodontitis patients but also our
ability to conduct more effective clinical and epidemiological
studies of this common, complex disease. The integration of
epidemiological studies of human health and disease with
detailed biomarker analysis would help to determine marker
sensitivity, specificity, and applicability; the UK Biobank
[21] and National Health and Nutrition Examination Survey
(NHANES) in the USA [186] are examples of resources that
might be thus exploited.
There has been some considerable interest in promoting
the dental clinic as a venue for general medical diagnosis
through physiological measurements (such as weight, height,
and blood pressure), finger stick blood tests, and salivary
diagnostics [21]. For example, screening in the dental clinic
for patients at risk of cardiac disorders is medically beneficial
[186]. Research in this area has shown that not only are dental
patients willing to donate saliva for diagnostic purposes but
also dentists themselves are willing to collect such samples
[187, 188]. Development of a practical framework for clinical
management of periodontitis using salivary biomarkers will
provide a paradigm for exploring the application of general
medical diagnostic procedures using saliva in the dental
clinic.
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